Popular terms

Antibodies topics
Antibodies
Recombinant
Nucleic Acid
Nucleic Acids
Polypeptide
Therapeutics
Immunoglobulin
Immunoglobulins
Monoclonal
Radiation Therapy
Desmoplastic
Hypertension
Hypertensive
Immunotherapy
Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibodies patents

      

This page is updated frequently with new Antibodies-related patent applications.




Date/App# patent app List of recent Antibodies-related patents
08/18/16
20160238606 
 Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens patent thumbnailnew patent Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens
The present invention relates to a plurality of antigens that together form a panel of immunoreactive molecules suitable for identifying candidates for prostate cancer examination. Methods for identifying antibodies indicative of a pre-malignant or malignant prostate are disclosed.
Wisconsin Alumni Research Foundation


08/18/16
20160238600 
 Method for selecting a single cell expressing a heterogeneous combination of antibodies patent thumbnailnew patent Method for selecting a single cell expressing a heterogeneous combination of antibodies
Described are combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. Further provided are methods for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing..
Merus B.v.


08/18/16
20160238597 
 Quantification of antigen molecules using dynamic flow cytometry patent thumbnailnew patent Quantification of antigen molecules using dynamic flow cytometry
The described invention provides a method for quantifying cellular antigens that is independent of specially prepared calibration beads and antibody reagents. The described method can be applied to both low and high affinity antibodies, under both saturating and non-saturating binding conditions..

08/18/16
20160237168 
 Methods for treating and preventing multiple sclerosis patent thumbnailnew patent Methods for treating and preventing multiple sclerosis
We have discovered that lrg-47 (also called p47 gtpase), plays a central role in the pathogenesis of multiple sclerosis, and that inhibition of lrg-47 activity by anti-lrg-47 antibodies or of lrg-47 expression by sirna dramatically reduce the pathology and symptoms of multiple sclerosis. Certain embodiments of the invention are directed to the therapeutic use of anti-lrg-47 antibodies (mouse or rabbit or other antibodies that are humanized or human antibodies to lrg-47, preferably antibodies made against human lrg-47) or sirna or antisense nucleotides that specifically hybridize with the gene or mrna or cdna encoding human lrg-47 to treat or prevent multiple sclerosis and other autoimmune diseases that are t-cell-mediated.
The Trustees Of Columbia University In The City Of New York


08/18/16
20160237165 
 Targeting intracellular target-binding determinants with intracellular antibodies patent thumbnailnew patent Targeting intracellular target-binding determinants with intracellular antibodies
The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first fv fragment with a cell-penetrating determinant and a second fv fragment with an intracellular target-binding determinant under suitable conditions so that the first fv fragment causes the bispecific antibody to enter the cell and the second fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target.. .
The United States Of America As Represented By The Department Of Veterans Affairs


08/18/16
20160237164 
 Anti-epcam antibodies and methods of use patent thumbnailnew patent Anti-epcam antibodies and methods of use
The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack t-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as fab, fab′, f(ab′)2, scfv, dsfv, ds-scfv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof.
Viventia Bio Inc.


08/18/16
20160237163 
 Patient-specific immunotherapy for treating heterogeneous tumors patent thumbnailnew patent Patient-specific immunotherapy for treating heterogeneous tumors
In the field of therapy, specifically patient-specific immune therapy for cancer, improved therapeutic modalities are provided for. The identity and dosage of the administered anti-tumor antibodies is determined and dynamically adjusted to the individual patient's condition, disease and/or treatment progression, thus providing anti-cancer treatment which may be particularly advantageous for the treatment of heterogeneous tumors..
Suri Technologies Ltd.


08/18/16
20160237162 
 Binding molecules specific for her3 and uses thereof patent thumbnailnew patent Binding molecules specific for her3 and uses thereof
Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the her3 receptor and inhibit various her3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with her3 mediated signal transduction..
Medimmune, Llc


08/18/16
20160237161 
 Antibodies against human cd38 patent thumbnailnew patent Antibodies against human cd38
Isolated monoclonal antibodies which bind to human cd38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies..
Genmab A/s


08/18/16
20160237160 
 Anti-tweakr antibodies and uses thereof patent thumbnailnew patent Anti-tweakr antibodies and uses thereof
The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the tweakr (tnfrsf12a, fn14). The antibodies, accordingly, can be used to treat tumors and other disorders and conditions associated with expression of the tweakr.
Bayer Pharma Aktiengesellschaft


08/18/16
20160237157 
new patent

Anti-fgfr4 antibodies and methods of use


The invention provides anti-fgfr4 antibodies and methods of using the same.. .
Genentech, Inc.


08/18/16
20160237154 
new patent

Antibody therapeutics that bind ctla4


There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.


08/18/16
20160237153 
new patent

Nav1.7 antibodies and methods of using the same


Disclosed herein is an antibody that binds to a voltage sensor paddle (vsp) of nav1.7. Also disclosed herein are methods of treating pain, itch, neurogenic inflammation, or cough in a subject in need thereof.
Duke University


08/18/16
20160237151 
new patent

Human anti-il-23 antibodies, compositions, methods and uses


A human anti-il-23p19 antibody, including isolated nucleic acids that encode at least one anti-il-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.. .
Janssen Biotech, Inc.


08/18/16
20160237147 
new patent

Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors


This invention provides antibodies that interact with or bind to human nerve growth factor (ngf) and neutralize the function of ngf thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing ngf function, and particularly for treating ngf-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-ngf antibodies.
E.r. Squibb & Sons, L.l.c.


08/18/16
20160237145 
new patent

Binding moieties for biofilm remediation


Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described.
Trellis Bioscience, Llc


08/18/16
20160237144 
new patent

Thermus thermophilus slyd fkbp domain specific antibodies


The present description relates to anti-thermus thermophilus slyd fkbp domain antibodies and methods of using the same.. .
Roche Diagnostics Operations, Inc.


08/18/16
20160237143 
new patent

Anti-hpv e7 antibodies


The present invention relates to monoclonal anti-hpv (human papillomavirus) e7 antibodies capable of specifically recognising an epitope of the c-terminal or the n-terminal region of a hpv e7 protein, diagnostic compositions and kits comprising said antibodies as well as methods for immunohistochemical and elisa-based diagnosis of hpv infections utilizing said antibodies.. .
Austria Wirtschaftsservice Gesellschaft Mbh


08/18/16
20160235861 
new patent

Glycoengineered antibody, antibody-conjugate and methods for their preparation


The invention relates to glycoengineered antibodies and antibody-conjugates. In particular, the invention relates to an antibody conjugate, prepared from igg antibody comprising at least two n-linked glycosylation sites on the combination of a single heavy chain and single light chain.
Synaffix. B.v.


08/18/16
20160235845 
new patent

Buffer formulations for enhanced antibody stability


The invention provides buffered formulations of adalimumab. The formulations comprise a buffer comprising an acetate salt, mannitol, glacial acetic acid, sodium chloride, and polysorbate 80.
Oncobiologics, Inc.


08/18/16
20160235833 
new patent

Chimeric factor h binding proteins (fhbp) and methods of use


Chimeric fhbps that can elicit antibodies that are bactericidal for different fhbp variant strains of n. Meningitidis, and methods of use, are provided..
Children's Hospital & Research Center Oakland


08/18/16
20160235832 
new patent

Compositions and the use of fibrinogen binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery


The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified n-terminus region, at least a portion of a modified c-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, c3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified n-terminus region, at least a portion of a modified c-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.. .
University Medical Center Utrecht, The Netherlands


08/18/16
20160235827 
new patent

Placental compositions for stimulation of immunity to pd-l1


Disclosed is the new, useful, and unexpected finding that immunization to placental endothelial cells stimulated with interferon gamma result in antibodies to the checkpoint inhibitor pd-l1. In one embodiment, the invention teaches the use of vallovax™ to induce immunological hyperresponsiveness and reduction of costimulatory need for t cell activation.
Batu Biologics, Inc.


08/18/16
20160235787 
new patent

Epitope spreading associated with car t-cells


The present invention relates to compositions and methods for inducing epitope spreading by administering to a mammal an effective amount of a cell genetically modified to express a chimeric antigen receptor (car). The invention also relates to identification of antigens and antibodies involved in the epitope spreading associated with car t cells..
The Trustees Of The University Of Pennsylvania


08/11/16
20160231339 

Reagent for assaying d-dimer and kit of reagent for assaying d-dimer


The present invention provides a reagent for assaying d-dimer which includes carriers sensitized to first and second monoclonal antibodies which react with d-dimer, but have different reactivity to d-dimer in which the first monoclonal antibody reacts with high- and low-molecular fractions of d-dimer, the second monoclonal antibody reacts with the high-molecular fraction, but reactivity of the second monoclonal antibody with the low-molecular fraction is different from that of the first monoclonal antibody and a kit of reagent for assaying d-dimer.. .
Sysmex Corporation


08/11/16
20160231338 

Method of detection of platelet-activating antibodies that cause heparin-induced thrombocytopenia/thrombosis


The present invention provides a method of detecting platelet activation in a patient, the method comprising the steps of a) obtaining a blood sample from a patient suspected of having heparin-induced thrombo-cytopenia (hit); b) incubating an effective amount of platelet factor 4 (pf4) with a sample of platelets to yield a sample of pf4-treated platelets; c) contacting the patient blood sample with the pf4-treated platelets; and d) measuring the extent of platelet activation, wherein an increase in platelet activation compared with results obtained using a normal blood sample is indicative of the patient having hit.. .
Blood Center Research Foundation


08/11/16
20160231328 

Human fc-bearing igg antibodies to polyethylene glycol


Polyethylene glycol (peg) is often conjugated with therapeutic proteins to enhance their pk properties. Peg may, however, be immunogenic, and the presence of peg in food and cosmetics is believed to result in pre-existing anti-peg antibodies in humans.
Bristol-myers Squibb Company


08/11/16
20160231322 

Immunohistochemical assay for detection of cd3 and cd16


The present application provides methods and systems for detecting both cd3 and cd16 in a sample using immunohistochemical methods, for example when the primary antibodies for cd3 and cd16 are from the same species (e.g., both rabbit antibodies). Methods to denature and block the first primary antibody contacted with the sample are provided..
Ventana Medical Systems, Inc.


08/11/16
20160230204 

Metabolically optimized cell culture


Improved methods for large scale production of proteins and/or polypeptides in cell culture is provided. In accordance with the present invention, the method provides for culturing cells that have metabolically shifted.
Regeneron Pharmaceuticals, Inc.


08/11/16
20160229924 

Heterodimeric antibodies that bind cd3 and tumor antigens


The present invention is directed to novel heterodimeric antibodies.. .
Xencor, Inc.


08/11/16
20160229923 

Anti-cea antibodies


The present invention provides antigen binding molecules (abms) which bind membrane-bound cea, including abms with improved therapeutic properties, and methods of using the same.. .
Roche Glycart Ag


08/11/16
20160229921 

Antibodies for botulinum neurotoxins


The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., bont/a, bont/b, bont/c, bont/d, bont/e, bont/f, bont/g, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism..
The Regents Of The University Of California


08/11/16
20160229920 

Targeting her2 and her3 with bispecific antibodies in cancerous cells


The disclosure provides monoclonal bispecific antibodies targeting her2 and her3. The disclosure also provides monospecific tetravalent her3 antigen binding antibodies.
Board Of Regents, The University Of Texas System


08/11/16
20160229919 

Mesothelin domain-specific monoclonal antibodies and use thereof


Described herein is the use of rabbit hybridoma technology, along with a panel of truncated mesothelin domain fragments, to identify anti-mesothelin mabs that bind specific regions of mesothelin. In one aspect of the present disclosure, the rabbit mabs bind an epitope that is not part of region i.
The U.s.a., As Represented By The Secretary, Department Of Health And Human Services


08/11/16
20160229918 

Tumor selective antibodies specific to oncofetal antigen/immature laminin receptor protein


Disclosed are high affinity antibodies or antigen binding fragments thereof, which bind an epitope that lies within the c terminal region of oncofetal antigen (ofa)/immature laminin receptor protein (ilrp), and which do not substantially cross-react with mature ofa/lrp. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy.
South Alabama Medical Science Foundation


08/11/16
20160229917 

Antagonist anti-il-7 receptor antibodies and methods


The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (il-7r). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids.
Rinat Neuroscience Corp.


08/11/16
20160229916 

High affinity antibodies to human il-6 receptor


A human antibody or an antigen-binding fragment which binds human il-6 receptor (hil-6r) with a kd of about 500 pm or less and blocks il-6 activity with an ic50 of 200 pm or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hil-6r with an affinity at least 2-fold higher relative to its binding monkey il-6r..
Regeneron Pharmaceuticals, Inc.


08/11/16
20160229914 

Method of treating a pathological syndrome


A method of treating disorder or condition that relates to intracellular signal transmission of a neurotransmitter, comprising administration of an homeopathically potentized form of antibodies to an antigen, which antigen is a molecule capable of effecting the intracellular signal transmission of a neuroreceptor, in particular dopamine or serotonin.. .

08/11/16
20160229911 

Antibody specific for cd22 and methods of use thereof


The present disclosure provides antibodies specific for an epitope present on cd22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided..
Redwood Bioscience, Inc.


08/11/16
20160229910 

Tm4sf1 binding proteins and methods of using same


This present invention relates to compounds (e.g., tm4sf1 binding proteins, e.g., anti-tm4sf1 antibodies) that specifically bind to a polypeptide at an epitope including an amino acid sequence of seq id no: 1. In particular, the compounds of the invention are capable of being internalized into a tm4sf1-expressing cell (e.g., a tumor cell or an angiogenic vasculature endothelial cell) following binding to the epitope of including the amino acid sequence of seq id no: 1.
Beth Israel Deaconess Medical Center, Inc.


08/11/16
20160229909 

Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof


Monoclonal antibodies against lrp6 and that block the wnt signaling pathway are disclosed. Methods of production and use thereof are also disclosed..
The Board Of Regents Of The University Of Oklahoma


08/11/16
20160229908 

Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof


One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous fc region variants that have decreased binding to pre-existing ada.
Chugai Seiyaku Kabushiki Kaisha


08/11/16
20160229824 

Assay for the detection of the phenylpiperazine family


The current invention describes novel immunogens which are used in the production of novel antibodies with unique binding properties in that they cross-react with a variety of phenylpiperazine derivatives. These antibodies enable methods and kits to detect and/or determine phenylpiperazine derivatives (for example mcpp, tfmpp and meopp) in an in vitro sample which are advantageous over currently available analytical methods in terms of cost, ease of use, speed and sensitivity..
Randox Laboratories Limited


08/11/16
20160228589 

Methods and compositions for imaging disorders using polyspecific agents


The present invention provides compositions and methods for detecting and/or monitoring a disease state with polyspecific imaging agents. In a particular embodiment, provided methods may be used to assess efficacy of anti-receptor tyrosine kinase and/or anti-cancer treatments.
Sloan-kettering Institute For Cancer Research


08/11/16
20160228571 

Anti-dll3 antibody drug conjugates


Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. .
Stemcentrx, Inc.


08/11/16
20160228549 

Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same


The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents.
Northwestern University


08/11/16
20160228546 

Modified antibody compositions, methods of making and using thereof


The present disclosure provides modified antibodies which contain an antibody or antibody fragment (ab) modified with a masking moiety (mm). Such modified antibodies can be further coupled to a cleavable moiety (cm), resulting in activatable antibodies (aas), wherein the cm is capable of being cleaved, reduced, photolysed, or otherwise modified.
Cytomx Therapeutics, Inc.


08/11/16
20160228522 

Oligomer-specific amyloid beta epitope and antibodies


A novel constrained peptide epitope derived from aβ, related antibody compositions and methods of use. An isolated antibody that specifically binds to a cyclic peptide comprising the conformational epitope corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric aβ is described.
The University Of British Columbia


08/11/16
20160228434 

Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor


An hdac6 inhibitor (a compound of formula i) is shown to reduce the pathogenesis associated with the b cell mediated autoimmune disease, systemic lupus erythematosus (sle) administration of a compound of formula i attenuated many of the symptoms characteristic of sle including splenomegaly, abnormal b cell differentiation, an increase in the number double-negative thymic t cells, an increase in the level of auto-antibodies such as anti-dsdna, immune complex-mediated glomerulonephritis and an increase in inflammatory cytokine production. Treatment with a compound of formula i also increased the number of the subject's splenic treg cells while removing circulating auto-antibodies inhibition of hdac6 altered bone marrow b cell differentiation by increasing the percentage of cells in the early-stage developmental fractions of both pro- and pre-b cells.
Virginia Tech Intellectual Properties, Inc.


08/04/16
20160223564 

Methods of detecting antibodies specific for denatured hla antigens


The invention is directed to methods of screening for hla antibodies comprising detecting antibodies specific for native hla antigens and denatured hla antigens. The invention also provides for methods of removing antibodies specific for denatured hla antigens or antibodies specific for native hla antigens from a serum sample.
One Lambda, Inc.


08/04/16
20160223563 

Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)


The present invention provides in vitro and in vivo diagnostic tests and methods for determining the safety, efficacy, or outcome of allergen-specific immunotherapy (sit) in a patient. The present invention also provides for the measurement of allergen specific igg and ige in a patient tissue sample, or extract thereof, or in a biological fluid or blood sample, and determining whether the allergen-specific immunoglobulins contained in the patient sample(s), upon injection into an allergen-sensitized animal, will protect the animal following challenge with the allergen.
Regeneron Pharmaceuticals, Inc.


08/04/16
20160223556 

Chemiluminescent protein chip, method and kit for detecting seroglycoid fucosylation index


A chemiluminescent protein chip, kit and method for detecting seroglycoid fucosylation index, in the field of protein detection technology. The chemiluminescent protein chip includes a substrate slide, at least one detection subarea, detection spot areas and one control spot area.
Beijing Youan Hospital, Capital Medical University


08/04/16
20160223541 

Method for measuring influenza b virus


A method for measuring influenza b virus by an immunoassay, which method enables specific detection of influenza b virus with a higher sensitivity than conventional methods, and a device or a kit therefor are disclosed. The method for measuring influenza b virus includes carrying out an immunoassay of influenza b virus by a sandwich method using two kinds of monoclonal antibodies each of which specifically reacts with the region of the 125th to 248th amino acids of matrix protein (m1) of influenza b virus, which two kinds of monoclonal antibodies are capable of binding to the region of the 125th to 248th amino acids of m1 at the same time, or antigen-binding fragments thereof..
Denka Seiken Co., Ltd.


08/04/16
20160222132 

Constant chain modified bispecific, penta- and hexavalent ig-m antibodies


The present invention concerns binding molecules having a penta- or hexameric ring structure, such as for example, isolated igm antibodies with five or six bispecific binding units, and methods and means for making and using the same. The invention further concerns multi-specific binding molecules having a penta- or hexameric ring structure, such as, for example, isolated igm antibodies with five or six bispecific binding units, and methods and means for making and using the same..
Igm Bioscienes, Inc


08/04/16
20160222129 

Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii


Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered..
Chugai Seiyaku Kabushiki Kaisha


08/04/16
20160222125 

Antibodies specific for claudin 6 (cldn6)


The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin-6 (cldn6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.. .
Johannes Gutenberg-universitat Mainz


08/04/16
20160222124 

Anti-cd40 antibodies


The present invention relates to new humanized antagonistic anti-cd40 antibodies and therapeutic and diagnostic methods and compositions for using the same.. .
Boehringer Ingelheim International Gmbh


08/04/16
20160222123 

Method treating neuronal tissue inflammation using an il-31ra monoclonal antibody


Use of antagonists to il-31ra and osmrb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof.
Zymogenetics, Inc.


08/04/16
20160222120 

Anti-b7-h1 antibodies for treating tumors


Provided herein are methods of treating b7-h1-expressing tumors comprising administering an effective amount of medi4736 or an antigen-binding fragment thereof.. .
Medlmmune Limited


08/04/16
20160222117 

Nucleic acid encoding anti-pd-l1 antibodies


The present application relates to nucleic acid encoding anti-pd-l1 antibodies, which have therapeutic use to enhance t-cell function to upregulate cell-mediated immune responses and for the treatment of t cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.. .
Genentech, Inc.


08/04/16
20160222116 

Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors


Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-lag-3 antibody in combination with an anti-pd-1 antibody.. .
Bristol-myers Squibb Company


08/04/16
20160222114 

Fully human antibodies to btla


The present invention relates to binding compounds specific for btla and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human btla and modulate its activity in cancer, inflammatory, and autoimmune disorders..
E.r. Squibb & Sons, L.l.c.


08/04/16
20160222113 

Antibodies against pd-1 and uses thereof


The present invention provides antibodies and antigen-binding fragments that specifically bind pd-1 (programmed death 1), thereby modulating immune responses in general, and those mediated by tcr and cd28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer and other immune system disorders..
Medimmune Limited


08/04/16
20160222107 

Methods of treating pain using function modifying nav1.7 antibodies


A nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.. .
Ucb Biopharma Sprl


08/04/16
20160222106 

Anti-cd38 antibodies for treatment of acute myeloid leukemia


The present invention relates to methods of treatment of acute myeloid leukemia with anti-cd38 antibodies.. .
Janssen Biotech, Inc.


08/04/16
20160222104 

Anti-il-6 antibodies, compositions, methods and uses


A pen-injector device comprising an anti-il-6 antibody with a liquid formulation have applications in diagnostic and/or therapeutic compositions, methods and devices.. .
Janssen Biotech, Inc.


08/04/16
20160222103 

Use of an il-31 monoclonal antibody for antagonizing signal transduction in spinal cord cells


Use of antagonists to il-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof.
Zymogenetics, Inc.


08/04/16
20160222102 

Methods of treating inflammatory diseases


This invention generally relates to methods for the treatment of il-23 related diseases, in particular inflammatory diseases, such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-spa), including ankylosing spondylitis and non-radiographic ax-spa, utilizing anti-il-23a antibodies.. .
Boehringer Ingelheim International Gmbh


08/04/16
20160222099 

Methods of treatment with angiopoietin-2 antibodies


The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against angiopoietin-2 (ang-2). Specifically, the disclosure is direct to the use of anti-ang2 antibodies or antigen-binding fragments thereof for treating ischemia.
University Of Helsinki


08/04/16
20160222098 

Nucleotide and amino acid sequences relating to respiratory diseases and obesity


This invention relates to genes identified from human chromosome 12q23-qter, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby.
Oscient Pharmaceuticals Corporation


08/04/16
20160222093 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160222092 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160222091 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160222090 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160222084 

Compositions comprising d-amino acid peptides and methods of production and use thereof for inhibiting autoantibodies


Compositions are disclosed that include d-amino acid peptides and that are capable of specifically binding to at least one autoantibody against a g-protein coupled receptor. The autoantibody is produced in a patient having or being predisposed to a disease condition or disorder, and the autoantibody is capable of binding to a specific epitope of the g-protein coupled receptor.
The Board Of Regents Of The University Of Oklahoma


08/04/16
20160222083 

Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin


Provided are compositions and methods that relate to prophylaxis and therapy of angiogenesis associated disease and includes novel knockin mice which express novel human/mouse chimeric endoglin, vectors for use in making such mice, and murine embryonic stem cells comprising the novel human/mouse transgene. Also provided are anti-human endoglin monoclonal antibodies (mabs) which can be used as antiangiogenic agents for prophylaxis or therapy of human tumor angiogenesis and human angiogenesis-associated diseases having excessive vascularization.
Health Research, Inc.


08/04/16
20160222070 

Compounds and methods for diagnosis and immunotherapy of tuberculosis


Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more mycobacterium proteins and dna molecules encoding such polypeptides.
Corixa Corpoation


08/04/16
20160220713 

Diagnosis of prostate cancer


Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post-operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled psa or hk2 specific antibodies, visualising psa or hk2 producing tissue with the aid of a visualisation method, and diagnosing prostate cancer from the difference in visualisation..

08/04/16
20160220671 

Method of administration to a patient suffering from disturbances in vascular tone


The method of treatment for diseases accompanied by disturbances of the vascular tone utilizes the use of ultra low doses of antibodies to a protein or a peptide involved in the vascular tone regulation or mediating the effects of other regulators; these antibodies are used in activated form produced by multiple subsequent dilution and external impact.. .

08/04/16
20160220669 

Combination therapy of antibodies against human csf-1r and tlr9 agonist


The present invention relates to the combination therapy of antibodies against human csf-1r with a tlr9 agonist.. .
Hoffmann-la Roche Inc.


08/04/16
20160220541 

Compositions, formulations and methods for treating ocular diseases


Disclosed herein are compounds effective for activation of tie-2 and inhibition of hptp-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions.
Aerpio Therapeutics, Inc.


08/04/16
20160220540 

Compositions, formulations and methods for treating ocular diseases


Disclosed herein are compounds effective for activation of tie-2 and inhibition of hptp-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions.
Aerpio Therapeutics, Inc.


08/04/16
20160219850 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160219849 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160219848 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160219847 

Common light chain mouse


A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline.
Regeneron Pharmaceuticals, Inc.


08/04/16
20160219846 

Animal models and therapeutic molecules


The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited


07/28/16
20160216269 

Anti-sox10 antibody systems and methods


The present invention is related to the anti-sox10 antibodies, kits, cocktails, and use of anti-sox10 antibodies for detection of cancer.. .
Biocare Medical, Llc


07/28/16
20160216267 

Detection of cancer using antibody arrays


Disclosed are antibody arrays for the detection of cancer in a human or animal subject, comprising a solid support having disposed thereon in a predetermined spatial configuration, a panel of antibodies specific to biomarkers comprising ca-125, msp-α, timp-4, pdgf-rα and opg, wherein the panel comprises a first antibody or fragment thereof that specifically binds ca-125, a second antibody or fragment thereof that specifically binds msp-α, a third antibody or fragment thereof that specifically binds timp-4, a fourth antibody or fragment thereof that specifically binds pdgf-rα, and a fifth antibody or fragment thereof that specifically binds opg. Also disclosed are systems containing the arrays and methods of using the arrays to detect cancer such as ovarian cancer..
South China Biochip Research Center In Guangzhou


07/28/16
20160216263 

Porcine torque teno virus vaccines and diagnosis


The present invention provides four purified preparation containing a polynucleic acid molecule encoding porcine torque teno virus (pttv) genotypes or subtypes pttv1a-va, pttv1b-va, pttv2b-va, and pttv2c-va. The present invention also provides infectious dna clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of the same.
Virginia Tech Intellectual Properties, Inc.


07/28/16
20160216262 

Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies


An in vitro method for quantifying a target-specific test antibody in a test sample, comprising the steps of: a) performing an immunoassay using a target immobilized on a support which is brought into contact with the test sample, the immunoassay comprising a step of measuring the binding of the target-specific test antibody to the immobilized target by using a detectable non-antibody ligand that binds to the fc region or to a light chain of an antibody, whereby a concentration-related value of the target-specific test antibody in the test sample is obtained, and b) comparing the concentration-related value obtained at step a) with a reference value obtained by performing an immunoassay using the target immobilized on a support which is brought into contact with a calibration sample comprising a known concentration of a target-specific calibration antibody, the immunoassay comprising a step of measuring the binding of the target-specific calibration antibody to the immobilized target by using the detectable non-antibody ligand of step a), and wherein: (i) the target-specific test antibody of step a) and the target-specific calibration antibody of step b) are identical, or (ii) the target-specific test antibody of step a) and the target-specific calibration antibody of step b) are distinct.. .
Assistance Publique Hopitaux De Paris


07/28/16
20160216252 

Plasmonic beads for multiplexed analysis by flow detection systems


Disclosed are methods and assays for detection of low concentration analytes such as proteins in a sample, using beads. Specially coated beads allow for femtomolar sensitivity through strong near-infrared fluorescence enhancement on plasmonic beads having gold nanostructures in a coating.
The Board Of Trustees Of The Leland Stanford Junior University




Antibodies topics: Antibodies, Recombinant, Nucleic Acid, Nucleic Acids, Polypeptide, Therapeutics, Immunoglobulin, Immunoglobulins, Monoclonal, Radiation Therapy, Desmoplastic, Hypertension, Hypertensive, Immunotherapy, Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.13

4890

3 - 0 - 104